GlaxoSmithKline PLC named CEO Designate Emma Walmsley and President of R&D Patrick Vallance to the board as executive directors, effective Jan. 1, 2017.
Stacey Cartwright will step down from the board, effective Dec. 31. She leaves after serving for almost 6 years as a nonexecutive director.
In addition, Andrew Witty and Moncef Slaoui will step down from the board March 31, 2017. Slaoui will serve as adviser to the company and the board from April 1, 2017, until his retirement June 30, 2017.